Literature DB >> 6521993

Retinal pigment epithelium decompensation. I. Clinical features and natural course.

A E Jalkh, N Jabbour, M P Avila, C L Trempe, C L Schepens.   

Abstract

We studied 97 eyes (73 patients) that showed a sharp contrast between the grossly normal appearance of the posterior pole by funduscopy and the fluorescein angiography findings of multiple patches of retinal pigment epithelium (RPE) transmission defect in the early transit, associated with focal areas of RPE staining in the late transit. The staining was located primarily at the superior edge of the RPE defect (63 eyes). The average age of the patients was 52.2 years at the time of diagnosis, and the ratio of men to women was 3.5 to 1. Ocular histories were unremarkable, except for 27 eyes with documented central serous retinopathy. Thirty-two consecutive eyes have been followed for an average of 3.9 years, and 30 of those eyes have shown visual deterioration.

Entities:  

Mesh:

Year:  1984        PMID: 6521993     DOI: 10.1016/s0161-6420(84)34095-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

1.  Three-dimensional imaging by spectral domain optical coherence tomography in central serous chorioretinopathy with fibrin.

Authors:  Sandeep Saxena; Neha Sinha; Shashi Sharma
Journal:  J Ocul Biol Dis Infor       Date:  2012-05-22

2.  Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy.

Authors:  L Ficker; G Vafidis; A While; P Leaver
Journal:  Br J Ophthalmol       Date:  1988-11       Impact factor: 4.638

3.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

4.  Familial central serous retinopathy.

Authors:  J A Oosterhuis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-05       Impact factor: 3.117

5.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

6.  Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

Authors:  S H Lim; W Chang; M Sagong
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

7.  Role of Avastin in management of central serous chorioretinopathy.

Authors:  Shaaban A Mehany; Ahmad M Shawkat; Mohamed F Sayed; Khaled M Mourad
Journal:  Saudi J Ophthalmol       Date:  2010-10-04

8.  Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.

Authors:  Pedro Cuevas; Luis A Outeiriño; Carlos Azanza; Javier Angulo; Guillermo Giménez-Gallego
Journal:  Eur J Med Res       Date:  2012-07-12       Impact factor: 2.175

9.  Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography.

Authors:  Hyung Chan Kim; Won Bin Cho; Hyewon Chung
Journal:  Korean J Ophthalmol       Date:  2012-09-24

10.  Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy.

Authors:  George D Tsakonas; Athanasios I Kotsolis; Chrysanthi Koutsandrea; Ilias Georgalas; Dimitrios Papaconstantinou; Ioannis D Ladas
Journal:  Clin Ophthalmol       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.